This is a preview of subscription content, log in via an institution to check access.
Reference
Shanafelt TD, et al. Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels. Journal of Oncology Practice : 24 Mar 2015. Available from: URL: http://dx.doi.org/10.1200/JOP.2014.002469
Rights and permissions
About this article
Cite this article
Access may be an issue for ibrutinib and idelalisib in CLL. PharmacoEcon Outcomes News 725, 5 (2015). https://doi.org/10.1007/s40274-015-2019-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2019-8